Management of neonatal thrombocytopenia in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group

Affiliation auteurs!!!! Error affiliation !!!!
TitreManagement of neonatal thrombocytopenia in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group
Type de publicationJournal Article
Year of Publication2019
AuteursBertrand G., Blouin L., Boehlen F., Levine E., Minon J-M, Winer N., Audrain M, Bayart S, Beguet M, Bierling P, Chabot V, Cortey A, Croisille L, Delettre F, Dupuis A, Fretigny M, Giannoli C, Goua V, Gruel Y, Harroche A, Hurtaud M-F, Jouannic J-M, Lafarge X, Le Toriellec E, Lecompte T, Macchi L, Makowski C, Mattiello V, Merieux Y, Mourey G, Pan-Petesch B, Pellegrinelli G, Petermann R, Peynaud-Debayle E, Picard C, Renac V, Rosenblatt J, Rugeri L, Turello R, Hemostasis FGrp Thromb
JournalARCHIVES DE PEDIATRIE
Volume26
Pagination191-197
Date PublishedAPR
Type of ArticleArticle
ISSN0929-693X
Mots-clésAlloimmunization, Human platelet antigen (HPA), Neonatal thrombocytopenia, Newborn, platelet, transfusion
Résumé

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a potentially devastating disease, seen in 1/800-1000 neonates. FNAIT is the most common cause of early-onset isolated severe neonatal thrombocytopenia in maternity wards. The most feared complication of this disorder is intracranial hemorrhage, leading to death or neurological sequelae. There is no systematic screening of at-risk pregnancies and FNAIT is often discovered when fetal or neonatal bleeding is observed. A working group on fetomaternal platelet alloimmunization was created in 2017, under the auspices on the French Group of Thrombosis and Hemostasis (GFHT). The first objective of this group was to survey clinical practices for treatment of thrombocytopenic neonates in a context of suspected or confirmed FNAIT. (C) 2019 Elsevier Masson SAS. All rights reserved.
DOI10.1016/j.arcped.2019.02.006